Ann: Acrux and Eli Lilly to appeal patent ruling on Axiron-ACR.AX, page-24

Would / could we change strategy and go generic? - I'm not convinced and the key remains in the fact that we are already competing with generics and must have a strategy to deal with it and the impending expirys anyway.

The @mita slide yesterday about the extent and growth in generics was probably the most telling (at 310316 grew rapidly to 20% market share, although growth in last 6 months much slower). So ACR need to factor in a reduction in sales revenue going forward, say about 80% going forward.

The question is how much of PAT will be distributed? - I'd say 60% - so 9E * 60% = say 5c

Re the action costs, ACR said somewhere there was no cost to ACR and the CFO confirmed this on the phone the other day, I assume Lilly also confirmed the same for the appeal?